Search
  • Admin

PYLOPASS™ | THE BIOACTIVEINGREDIENT AGAINST HELICOBACTER PYLORI

Updated: Apr 10






WHAT IS HELICOBACTER PYLORI?


  • A gram negative, spiral-shaped human pathogen, infecting anestimated 50% of the global population.

  • One of the most frequent and persistent bacterial infections worldwide.

  • Associated with several gastrointestinal diseases such as peptic ulcer disease, gastric ulcers, mucosa-associated lymphoid tissue lymphoma and gastric cancer.

  • Able to adapt and survive in the acidic environment of the stomach, and adhere to the mucosa.

  • Able to adapt and survive in the acidic environment of the stomach, and adhere to the mucosa.

  • High levels can lead to increased acute mucosal damage and long-term changes in the gastric mucosa.

  • Has been classified as a class I carcinogen by the World Health Organization.

  • High levels can lead to increased acute mucosal damage and long-term changes in the gastric mucosa.

  • Has been classified as a class I carcinogen by the World Health Organization.



PYLOPASS™ REDUCES BACTERIAL LOAD OF HELICOBACTER PYLORI




  • A patented strain of Lactobacillus reuteri that was identified in a detailed, multi-year screening process from several thousand food grade strains.

  • Has been selected to specifically recognize and bind Helicobacter pylori under harsh stomach conditions.

  • Exhibits co-aggregation mechanism as a unique and selective mode of action.

  • Has a shelf-life of minimum 3 years at room temperature, with guaranteed high activity.



PYLOPASS™ SUPPLEMENTATION SIGNIFICANTLY REDUCES H. PYLORI LOAD

  • Reduction of H. pylori levels in the stomach is demonstrated across all published clinical studies.

  • Study 1 and 2 demonstrated significant reduction at two and six months after consumption of Pylopass™.

  • Study 3 demonstrated eradication of H. pylori in several cases.

  • No side-effects seen.

NOTES: ¹³C-Urea Breath Test is a way of testing for Helicobacter pylori bacterium.



PYLOPASS™ SUPPLEMENTATION IMPROVES QUALITY OF LIFE

  • Increase in well-being after eating from 50% to 75% of the subjects in Study 3 following 14 and 28 days of supplementation with Pylopass™.



REFERENCES:

  1. Mehling H & Busjahn A (2013) Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to H. pylori control. Nutrients 5: 3062-3072.

  2. Holz C. et al (2014) Significant reduction of Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A pilot study. Probiotics & Antimicro. Prot. 7: 91-100.

  3. Bordin DS et al. (2016) Efficacy and safety of Lactobacillus reuteri DSMZ17648 in Helicobacter pylori infection with no indications for absolute eradication therapy. THERAPIST. 5, www.lvrach.ru.

0 views

© 2018 AQURATE INGREDIENTS INTL (M) SDN BHD. - Shares What's Accurate. All Rights Reserved.